Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracyclin... von Kaufman, Peter A, Awada, Ahmad, Twelves, Chris, Yelle, Louise, Perez, Edith A, Velikova, Galina, Olivo, Martin S, He, Yi, Dutcus, Corina E, Cortes, Javier

Volltext

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 von ELLARD, Susan L, CLEMONS, Mark, SAUERBREI, Eric, MISHAELI, Moshe, HUNTSMAN, David, WALSH, Wendy, OLIVO, Martin, MCINTOSH, Lynn, SEYMOUR, Lesley, GELMON, Karen A, NORRIS, Brian, KENNECKE, Hagen, CHIA, Stephen, PRITCHARD, Kathleen, EISEN, Andrea, VANDENBERG, Ted, TAYLOR, Marianne

Volltext

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer von Rugo, Hope S., Tolaney, Sara M., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Hurvitz, Sara A., O’Shaughnessy, Joyce, Cortés, Javier, Diéras, Véronique, Carey, Lisa A., Gianni, Luca, Piccart, Martine J., Loibl, Sibylle, Goldenberg, David M., Hong, Quan, Olivo, Martin, Itri, Loretta M., Kalinsky, Kevin

Volltext

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer von Twelves, Chris, Awada, Ahmad, Cortes, Javier, Yelle, Louise, Velikova, Galina, Olivo, Martin S., Song, James, Dutcus, Corina E., Kaufman, Peter A.

Volltext

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer von Rugo, Hope S., Tolaney, Sara M., Loirat, Delphine, Punie, Kevin, Bardia, Aditya, Hurvitz, Sara A., O’Shaughnessy, Joyce, Cortés, Javier, Diéras, Véronique, Carey, Lisa A., Gianni, Luca, Piccart, Martine J., Loibl, Sibylle, Goldenberg, David M., Hong, Quan, Olivo, Martin, Itri, Loretta M., Kalinsky, Kevin

Volltext

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies von Twelves, Chris, Cortes, Javier, Vahdat, Linda, Olivo, Martin, He, Yi, Kaufman, Peter A., Awada, Ahmad

Volltext

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study von Kogawa, Takahiro, Yonemori, Kan, Masuda, Norikazu, Takahashi, Shunji, Takahashi, Masato, Iwase, Hirotaka, Nakayama, Takahiro, Saeki, Toshiaki, Toyama, Tatsuya, Takano, Toshimi, Onuma, Hiroshi, Ogawa, Hayao, Tanaka, Yoshimi, Igari, Yoshiko, Sugihara, Masahiro, Vigliotti, Michele, Yu, Channing, Olivo, Martin Sebastian, Ueno, Suguru, Iwata, Hiroji

Volltext

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms von Saini, Kamal S, de Las Heras, Begoña, Plummer, Ruth, Moreno, Victor, Romano, Marco, de Castro, Javier, Aftimos, Philippe, Fredriksson, Judy, Bhattacharyya, Gouri Shankar, Olivo, Martin Sebastian, Schiavon, Gaia, Punie, Kevin, Garcia-Foncillas, Jesus, Rogata, Ernesto, Pfeiffer, Richie, Orbegoso, Cecilia, Morrison, Kenneth, Curigliano, Giuseppe, Chin, Lynda, Saini, Monika Lamba, Rekdal, Øystein, Anderson, Steven, Cortes, Javier, Leone, Manuela, Dancey, Janet, Twelves, Chris, Awada, Ahmad

Volltext

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer von Bardia, Aditya, Hurvitz, Sara A, Tolaney, Sara M, Loirat, Delphine, Punie, Kevin, Oliveira, Mafalda, Brufsky, Adam, Sardesai, Sagar D, Kalinsky, Kevin, Zelnak, Amelia B, Weaver, Robert, Traina, Tiffany, Dalenc, Florence, Aftimos, Philippe, Lynce, Filipa, Diab, Sami, Cortés, Javier, O’Shaughnessy, Joyce, Diéras, Véronique, Ferrario, Cristiano, Schmid, Peter, Carey, Lisa A, Gianni, Luca, Piccart, Martine J, Loibl, Sibylle, Goldenberg, David M, Hong, Quan, Olivo, Martin S, Itri, Loretta M, Rugo, Hope S

Volltext

A NOTE ON THE SEMILOCAL CONVERGENCE OF CHEBYSHEV’S METHOD von DILONÉ, MANUEL A., GARCÍA-OLIVO, MARTÍN, GUTIÉRREZ, JOSÉ M.

Volltext

SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study von Zhao, Yuanyuan, Zhang, Li, Fang, Wenfeng, Yang, Yunpeng, Huang, Yan, Zou, Wen, Wang, Zhaoxiang, Ding, Muran, Peng, Yujia, Xiao, Sa, Wang, Hongwei, Zhu, Hai, Olivo, Martin Sebastian, Zhu, Yi

Volltext

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 st... von Zhang, Li, Ma, Yuxiang, Zhao, Yuanyuan, Fang, Wenfeng, Zhao, Hongyun, Huang, Yan, Yang, Yunpeng, Chen, Likun, Hou, Xue, Zou, Wen, Ding, Muran, Yu, Jing, Zhang, Suoyu, Wang, Junxian, Xiao, Sa, Wang, Hongwei, Zhu, Hai, Olivo, Martin Sebastian, Zhu, Yi

Volltext

SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study von Wang, Yakun, Li, Yongsheng, Liu, Jiyan, Luo, Su-xia, Li, Qi, Zou, Wen, Wang, Zhaoxiang, Peng, Yujia, Xiao, Sa, Wang, Hongwei, Zhu, Hai, Olivo, Martin Sebastian, Zhu, Yi, Shen, Lin

Volltext

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cel... von Xue, Liqiong, Yang, Kunyu, Fang, Meiyu, Ma, Xuelei, Zou, Wen, Ding, Muran, Wang, Zhaoxiang, Peng, Yujia, Xiao, Sa, Wang, Hongwei, Zhu, Hai, Olivo, Martin Sebastian, Zhu, Yi, Guo, Ye

Volltext

GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale von Wang, Jianxiang, Qi, Junyuan, Li, Wenyu, Zhai, Zhimin, Li, Ping, Zou, Wen, Ding, Muran, Yang, Xue, Wang, Rong, Guo, Wanjing, Xiao, Sa, Khalili, Jahan S., Zhu, Hai, Olivo, Martin Sebastian, Zhu, Yi

Volltext

Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes von Majid, Oneeb, Gupta, Anubha, Reyderman, Larisa, Olivo, Martin, Hussein, Ziad

Volltext

Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 n... von Rugo, Hope S, Bardia, Aditya, Tolaney, Sara M., Arteaga, Carlos, Cortes, Javier, Sohn, Joohyuk, Marmé, Frederik, Hong, Quan, Hofsess, Scott, Olivo, Martin, Fabrice, André, Schmid, Peter

Volltext

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy von Twelves, Christopher, Cortes, Javier, Kaufman, Peter A, Yelle, Louise, Awada, Ahmad, Binder, Terri A, Olivo, Martin, Song, James, O'Shaughnessy, Joyce A, Jove, Maria, Perez, Edith A

Volltext

Peripheral neuropathy (PN) in patients (pts) with metastatic breast cancer treated with eribulin: Resolution and association with efficacy von Kaufman, Peter, Olivo, Martin, He, Yi, McCutcheon, Susan, Vahdat, Linda

Volltext

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function von Tan, Antoinette R., Sarantopoulos, John, Lee, Lucy, Reyderman, Larisa, He, Yi, Olivo, Martin, Goel, Sanjay

Volltext